Abstract:Boron-dipyrromethene (BODIPY) dyes have aroused considerable interest in cancer theranostics over the past decade because of robust photochemical properties. Although a large number of BODIPY photosensitizers (PSs) containing heavy atoms have been reported, the development of heavy-atom-free BODIPY PSs for oncologic photodynamic therapy (PDT) has been limited mainly by the uncertainty in intersystem crossing (ISC) mechanisms, unbalanced phototoxic effectiveness and fluorescence quantum yields, and aggregation-caused quenching effects. In addition, the lack of extensive in vivo studies of heavy-atom-free BODIPY PSs continues to limit clinical application. Herein, novel heavy-atom-free BODIPY-phenoxazine triads (BDP-8/BDP-9) that generate efficient excited triplet states via radical pair intersystem crossing (RP-ISC) followed by triplet charge recombination were developed for use in fluorescence image-guided PDT. BDP-8/BDP-9 exhibited high molar absorption coefficients, prominent aggregation-induced emission, and excellent singlet oxygen generation capability upon light irradiation. The corresponding BODIPY nanoparticles (BDP-8/BDP-9 NPs) with bright red emission, considerable phototoxicity, and excellent tumor-targeting ability were simply prepared by encapsulating BDP-8/BDP-9 PSs in a polymeric matrix. More importantly, the results of both in vitro and in vivo experiments demonstrated the considerable potential of BDP-8 NPs for image-guided photodynamic cancer therapy. This study may inspire the development of potential BODIPY-based nanoagents for cancer theranostics.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.chemmater.1c02776.Experimental data; synthesis, nanoparticle preparation, photophysical measurements, and reactive oxygen species measurements of BDP-8/BDP-9; in vitro and in vivo studies of BDP-8/BDP-9 NPs; 1H and 13C NMR spectra of all compounds; UV–vis absorption and PL spectra; fluorescence images; computational details, calculated electronic transition energies; energy gap between single and triplet states; spin-orbit coupling constant; and intersystem crossing rate constant (PDF)This article has not yet been cited by other publications.

Identification of a luminescent platinum(II) complex with BODIPY derivative as novel photodynamic therapy agent for triple negative breast cancer cells

Novel Naphthalimide Bridged Zinc Porphyrin/bodipy Nanomaterials with D-A Structure for Photodynamic Therapy

Novel BODIPY-based Nano-Biomaterials with Enhanced D-A-D Structure for NIR-triggered Photodynamic and Photothermal Therapy

Platinated Porphyrin As A New Organelle and Nucleus Dual-Targeted Photosensitizer for Photodynamic Therapy

Cisplatin-appended BODIPY for near infrared II fluorescent and photoacoustic imaging-guided synergistic phototherapy and chemotherapy of cancer

BODIPY-based Monofunctional Pt (II) Complexes for Specific Photocytotoxicity Against Cancer Cells

Dual stimuli-activatable versatile nanoplatform for photodynamic therapy and chemotherapy of triple-negative breast cancer

Dendron‐Functionalized Polyglutamate‐Pyropheophorbide‐a Conjugates as Nanomedicines for Breast Cancer Photodynamic Therapy

A Near-Infrared and Lysosome-Targeted Coumarin-Bodipy Photosensitizer for Photodynamic Therapy Against HepG2 Cells

Access to the Triplet Excited States of Heavy-Atom-Free Boron-Dipyrromethene Photosensitizers via Radical Pair Intersystem Crossing for Image-Guided Tumor-Targeted Photodynamic Therapy

Tumor Microenvironment Activated and Amplified Self-Luminescent Nano Photosensitizers for Efficient Treatment of Triple Negative Breast Cancer

Periodic Mesoporous Organosilica Coupled with Chlorin E6 and Catalase for Enhanced Photodynamic Therapy to Treat Triple-Negative Breast Cancer

An advanced multifunctional prodrug combining photodynamic therapy with chemotherapy for highly efficient and precise tumor ablation

Single molecular-based nanoparticles with aggregation-induced emission characteristics for fluorescence imaging and efficient cancer phototherapy

Discovery of Subcellular-Targeted Aza-BODIPY Photosensitizers for Efficient Photodynamic Antitumor Therapy.

Cationic BODIPY Photosensitizers for Mitochondrion-Targeted Fluorescence Cell-Imaging and Photodynamic Therapy

Mitochondria-targeting BODIPY-loaded Micelles As Novel Class of Photosensitizer for Photodynamic Therapy

Uridine-Modified Ruthenium(II) Complex as Lysosomal LIMP-2 Targeting Photodynamic Therapy Photosensitizer for the Treatment of Triple-Negative Breast Cancer

Tumor oxygenation nanoliposomes promote deep photodynamic therapy for triple-negative breast cancer

Ultrasound-targeted photodynamic and gene dual therapy for effectively inhibiting triple negative breast cancer by cationic porphyrin lipid microbubbles loaded with HIF1α-siRNA.

The halogen effect of bis-truxene substituted BODIPY photosensitizers for potential photodynamic therapy